Thank you, operator, and good afternoon, everyone. Welcome to Starling Oncology's Second Quarter 2026 Earnings Conference Call.

I'm Minh Merchant, Chief Legal Officer, and joining me today are Dan Virnich, our Chief Executive Officer; and Rob Carter, our Chief Financial Officer. The press release announcing our results for the second quarter of 2026 is available in the Investor Relations section of our website, starlingoncology.com.

A replay of this call will also be available on our website following its conclusion. Before we get started, I'd like to remind you of the company's safe harbor language included within our press release for the second quarter of 2026.

Management may make forward-looking statements, including guidance and underlying assumptions. These forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially.

For a further discussion of risks related to our business, please see our filings with the SEC, including our most recent Form 10-Q for the quarter ended June 30, 2026. This call will also discuss non-GAAP financial measures such as adjusted EBITDA, MLR and free cash flow.

A reconciliation of these non-GAAP measures to the most comparable GAAP measures is included in the earnings release furnished to the SEC and available on our website. With that, I'll turn the call over to Dan.

Thank you, Minh. Good afternoon, everyone, and thank you for joining our second quarter 2026 earnings call.

We are reporting a very strong second quarter with profitability and completion of a strategic refinancing. And we've had a very exciting summer so far with a lot of positive momentum in our business.

Before I get into our results, I want to share an important announcement. The company has decided to rebrand as Starling Oncology.

As we have transformed this business over the past several years, our prior name no longer reflected our scope as a national value-based oncology leader. Our new name, Starling Oncology, is inspired by the coordinated flying patterns of starlings called murmurations.

This symbolizes the coordinated care, community access and technology-driven innovation that define our approach to value-based oncology care. This rebrand comes at a pivotal moment in our company's evolution.

After rebuilding the organization, achieving profitability, scaling our value-based care capabilities, strengthening our operations and establishing a foundation for future growth, we believe our brand should now reflect the company we have become. While our name is changing, our mission remains the same, delivering high-quality patient-centered cancer care in the communities we serve.

Turning to our financial results. The second quarter saw revenue of approximately $161 million, an increase of 35% year-over-year, driven by strong capitated growth in our specialty pharmacy business.

I'm also pleased to report that we have achieved positive adjusted EBITDA and came in at the top end of our guidance range in the second quarter due to continued growth, strong MLR performance on our risk contracts and operational efficiencies as we scale. This marks our second profitable quarter as a public company.

As we continue to scale, we are finding additional OpEx efficiencies across the business. Last quarter, we announced a substantial update to our free cash flow guidance due to payment term negotiations with key vendors.

I'm pleased that the progress continued in Q2 as we negotiated fee reductions with another key vendor partner that will substantially lower our cost to collect on non-capitated encounters and resulted in over $1 million in OpEx savings annualized at our current size. Next, as discussed on our last call, we're launching our new provider portal, Starling Nexus in mid-August.

We'll be rolling this out in a phased approach, onboarding our MSO-affiliated physicians in September and PC employed physicians later this year. Once fully launched, all of our providers, both PC employed and network providers will use the portal to submit treatment orders and obtain pre-authorizations from us, which we believe will drive increased adherence to our clinical care pathways.

In addition, the portal will be a hub to drive ancillary services such as our Part D pharmacy, decentralized clinical trials and other value-add offerings to our network providers, which will create tremendous value for our important network practices and for Starling. Lastly, Starling Nexus will provide an immense amount of data on practice patterns, and patient care being delivered across our network, which will allow us to continue to excel on MLR performance and create valuable data insights to partners over time.

In addition to a strong second quarter, we're also excited to share several announcements from July and August. First, on new capitated contracts, we anticipate adding 3 new delegated capitated contracts at the start of Q4, which is notable in that 2 of them are occurring in Nevada and Oregon, representing our first expansion of this model with health plan partners outside of Florida.

In total, these 3 contracts represent approximately 80,000 additional aggregate lives and approximately $50 million in annualized capitated revenue, not including the downstream benefit of wraparound services like pharmacy. I'm also pleased to announce that we achieved exclusivity in California with one of our largest partners across all of their delegated medical groups, a relationship that was previously split with another entity.

This added approximately 230,000 capitated lives and an estimated additional $6 million annualized capitation revenue in addition to associated Part D growth. Lastly, our statewide payer relationship in Florida that we announced on our Q2 call has been pushed from Q3 to Q4 in terms of effective date.

Finally, as many of you saw, last month, we announced a strategic refinancing that strengthened our balance sheet and improved our liquidity by replacing a convertible note that was nearing maturity with a new term facility. Rob will discuss this in more detail in a few minutes, but I want to say how pleased we are with the results and the additional financial flexibility, this affords us.

Our results in the first half of the year have given us the opportunity to raise our outlook for the full year. We are raising our revenue and gross profit ranges and tightening our adjusted EBITDA range.

2026 will still mark our first year of positive adjusted EBITDA as a public company while allowing us to continue investing in the business ahead of an expected 100% increase in capitated revenue next year. Wrapping up, I'm very pleased with the momentum we're seeing so far this year.

The business is continuing to track to increasing profitability quarter-over-quarter in 2026. Our capitated contract growth remains robust.

We see ongoing strong MLR performance and our Part D business is continuing to set monthly fill records. I look forward to keeping you posted on our progress as we move forward at Starling Oncology.

I'll now turn it over to Rob to review our financial results in more detail. Rob?

Thanks, Dan, and good afternoon, everyone. Building on what Dan shared, I'm equally encouraged by the momentum we continue to see across the business.

On the call today, I will provide some color on our improved capital structure, review our second quarter financial results, including additional transparency we are providing into our medical costs, touch on our balance sheet and cash flow and close with our updated guidance and outlook. I'm pleased to report that we completed a strategic refinancing with OrbiMed in July following repaying the $86 million senior secured convertible note that had been outstanding.

Under the new arrangement, we repaid that balance with a $75 million term loan from OrbiMed, along with approximately $11 million of cash on the balance sheet, and we did this without raising additional equity or diluting our shareholders. This is a meaningful step for us.

It extends our debt maturities from 2027 out to 2031, improves our liquidity and operating flexibility and gives us committed funding as we continue to scale the business. Turning to our second quarter financial results.

Total revenue was $161.3 million compared to $119.8 million in the prior year period, representing 34.6% year-over-year growth, an extension of the strong momentum we've been generating. Patient services revenue, which includes both our capitated and fee-for-service arrangements was $58.8 million, representing 36.5% of total revenue and a 5.3% year-over-year increase.

Specialty Pharmacy revenue was $98.6 million, representing 61.1% of total revenue and growing 57.6% year-over-year. This was driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the ongoing ramp of our Florida delegated arrangements.

Gross profit for the second quarter was $27.2 million compared to $17.5 million in the second quarter of 2025, reflecting continued top line expansion across both segments. Overall gross margin was 16.8% compared to 14.6% in the prior year, an improvement of approximately 225 basis points.

Patient Services gross profit was $2.1 million compared to $4.7 million in the second quarter of 2025, a decline of approximately 57%. There are 3 drivers of this decline: First is an increase in clinical labor as we staff ahead of our new contract launches; second is our conservative fee-for-service approach mentioned in our first quarter earnings call; and third, a natural increase in MLR as we onboard new lives.

In an effort to provide increased transparency and allow you to better assess the health of our capitated model, beginning this quarter, we are providing a medical loss ratio for all of our capitated members. MLR for the second quarter was 85.5% compared to 71% a year ago.

MLR will reflect not only our medical cost trends, but is anticipated to fluctuate as we onboard delegated members. That said, we anticipate that MLRs will be in the range of 80% to 90% in the next 12 months.

Specialty Pharmacy gross profit was $21.3 million, growing 85.1% year-over-year from $11.5 million in the prior year period. Gross margin improved to 21.6%, up from 18.4% a year ago, reflecting the continued benefit of scale, procurement optimization and our clinical pathways utilization management as the pharmacy grows.

Moving to operating expenses. Second quarter SG&A came in at $29.9 million or 18.6% of revenue, down from $26.9 million or 22.5% of revenue a year ago.

Roughly 390 basis points of improvement. That reflects the operating leverage built into our model as we scale along with the cost discipline we've maintained throughout the business.

Adjusted EBITDA for the second quarter was $0.2 million compared to a loss of $4.1 million a year ago and within the range we guided to on our last call. This represents an improvement of approximately $4.3 million, consistent with the seasonal pattern we described and reflects the continued ramp of our Florida delegated arrangements, growth in specialty pharmacy and ongoing cost discipline.

We ended the quarter with $41.1 million in cash and cash equivalents compared to $33.6 million at year-end 2025. Operating cash flow for the 6-month period was a positive $9.7 million compared to a use of $15.2 million in the second quarter of last year, reflecting the improvement in adjusted EBITDA, together with favorable working capital dynamics, including the timing of accounts payable.

Free cash flow for the second quarter was approximately $12.5 million, bringing year-to-date free cash flow to $9.5 million compared to a use of $14.6 million in the first half of 2025, an improvement of over $24 million. Turning to guidance.

For the full year, we are raising our revenue and gross profit ranges to reflect the strength we have seen in the first half of the year. We are also narrowing our adjusted EBITDA range to reflect a delegated contract launch that was pushed by 2 months until October 1 as well as investments we are making in the business to support the capitated revenue growth we expect for next year.

We now expect revenue of $650 million to $670 million, including approximately $150 million of capitation revenue, gross profit of $105 million to $110 million, adjusted EBITDA of $2 million to positive $7 million, and we still expect free cash flow in the range of positive $5 million to positive $15 million. For the third quarter, we anticipate adjusted EBITDA to be positive but muted in the range of $500,000 to $1.5 million as we onboard the aforementioned 230,000 new members and they begin to ramp.

We expect momentum to build through the remainder of the year and remain confident in our commitment to full year positive adjusted EBITDA. With that, I'll turn the call over to Dan for his closing remarks.

Dan?

In conclusion, we are excited to report a second quarter that demonstrated record revenue, positive adjusted EBITDA, a successful refinancing of our legacy debt and ongoing robust value-based contract growth. Before we open the call for questions, I want to thank our patients for putting their trust in us and to thank our physicians, clinicians and employees across Starling Oncology for their continued dedication.

Operator, we're now ready to take questions.

Congratulations on the great quarter. Can you maybe talk a little bit about the Nevada and Oregon expansions?

How did those come about? Those sound like solid wins.

What does the membership look like, the incremental revenue contribution? Just any more color there would be very helpful.

Dave, thanks for the question. This is Dan.

So there's one contract in each state, one in Nevada, one in Oregon. Both contracts together, as we commented on -- in the call, have a fairly substantial contribution in terms of both membership around 80,000 and then the revenue we mentioned.

Those are both delegated capitation contracts direct to health plan partners. The Oregon contract will be a statewide delegated contract with a health plan.

And the Nevada contract will be based in Clark County on behalf of members tied to a specific payer.

That's great. And did I hear that the MLR is in the 80% to 90% range?

That sounds pretty good, actually. A lot of the plans are talking about like, 95%.

Just any more thoughts there would be very helpful.

Dave, it's Rob. Yes, as we've discussed before, we segment our MLR between our various cap products.

So, on the delegated product, we're looking at MLR between 75% to 85% once fully ramped. Because of the influx of so many delegated lives, we're guiding towards 80% to 90% in the next 12 months, which is something we're still quite proud of.

And as a reminder, on our narrow network products outside of Florida, those are in the 70% to 75% range.

Okay. Great.

And then it just sounded to me like the incremental expansion in California sounds promising. Just any thoughts around what drove that?

And in my mind, all the health plans are talking about higher MLR trend, oncology, medications costs being a driver of that. It seems to me like you can bring a pretty good solution to Medi-Cal or health plans broadly speaking.

So any more thoughts around like what led to that win?

Great question, and apologies, I'm losing my voice a little bit. But what mainly led to that win was just outperforming on service, providing better access to members through our expansive network in California, better coordination of care with primary care physicians referring specialists.

As noted, that was previously a contract that was split with another entity, and we just outperformed on access and coordination of care. As we commented in the call, the annualized contribution from a capitation revenue perspective of those additional 200-plus thousand members is relatively small when you compare it to the Nevada and Oregon contracts we were just discussing.

The reason for that is the heavy predominance of Medi-Cal membership, which because of the lower prevalence rates in the younger population has a lower cap rate. That being said, it's still an enormous amount of transition of care into our organization and will tie things like Part D revenue as those members come to us for care and get those medication fills.

So most importantly, I think we're just proud of the fact that it came from the existing relationship and shows confidence in our model given our partners' ability to expand with us.

If you can make margin in Medi-Cal, you can probably make margin anywhere, especially Medicare in other regions of the country. So congrats on the great quarter.

I'll hop back in the queue.

Congrats on another really nice quarter here and especially under the new name. Maybe I want to start there.

Just with the rebrand, like, what's your thinking on why now? Just thinking we're midyear, mid-scaling in certain markets.

So just kind of curious what drove the timing? And then I think in past calls, word-of-mouth referrals were starting to become a theme in more mature markets.

So do you have any concerns about the name change causing confusion? Or is there sort of a marketing plan in place to help drive awareness of the new brand?

It would be good to just kind of get some more color around the rebranding.

Yes. The rebranding really came about because our legacy name as we had heard for many years from everyone from payers to patients to referring specialists drew a lot of confusion.

Oncology Institute of Hope and Innovation had connotations of being a clinical trials organization or a faith-based organization or an organization that was how -- very [indiscernible] based. It didn't really reflect what we do.

And this being a year where we have this pivotal transition into a profitable public company, really phenomenal growth in terms of expansion of our capitated partnerships. The time just seemed right, and we wanted to tie that with the launch of our Nexus provider portal.

So that's why we did it this quarter. In terms of ensuring that there's smooth brand recognition with the new Starling Oncology name with both our existing and future partners, we have a very targeted communication campaign, which we launched this week.

We ensure that all of our existing partners know about the name change, are aware of the reasons for the change. Same thing with all of our pipeline conversations.

So we don't anticipate any disruptions in growth or anything else related to the actual name change itself.

Okay. Good to hear.

Maybe on the provider portal, good to hear that, that's still on pace for Q3. Have you started doing any early marketing or provider education ahead of that launch, maybe beta testing in smaller groups or anything kind of less than the formal launch?

And then more importantly, will e-prescribing be functional at go-live? Or does that capability lag the initial rollout?

Yes. So we are fully launching that product in terms of external PR at mid-August.

We've already soft launched the product in terms of enabling access for providers in our network this month. So that's already live.

In terms of integration of e-prescribe on Part D, that's going to lag the initial launch by about a month or so as we work through some integration. So I expect that to come live in probably the September to early October time frame.

Okay. And still nothing assumed in the guidance in terms of any Part D lift related to the portal rollout, correct?

No, nothing.

Okay. And then last one for me.

I just want to follow up on the achievement of exclusivity in that California partner. So obviously kicked out an incumbent oncology vendor.

Is that a trend you're seeing in other places? Or should we take this to mean like this is a signal of broader trend of partners or plans collapsing split oncology arrangements?

Like are you seeing this opportunity with any other partners or plans as you look at kind of your current book of partners?

I can speak to our experience, it's really been more about winning business from competitors than consolidation per se. This is clearly a service-related win.

And then service and price seem to be the way we're winning in other markets, too, in terms of taking on new contracts from competitors.

Congrats on a good quarter. Maybe just to clarify, I want to double check.

Did you guide 2027 capitated business to double, meaning $300 million?

That is correct, Yuan. Yes, we're guiding this year $250 million of capitated revenue, so spot on.

And for the $300 million, are we saying that the whole year revenue from capitated business is $300 million or is more of a run rate by 4Q 2027?

I'm not 100% sure I got that whole thing. So we guided specifically to 2 tranches of launches.

In the first quarter call, we guided to our full state Florida expansion. And then in this call right now, we talked about the 80,000 lives in Oregon and Nevada as well as the 230,000 lives through the expansion in California.

So those are the basis of the growth in CAP, but the pipeline is robust, and there will be additional growth on top of that.

Got it. Got it.

And then maybe a little bit more color on the Florida contract pushing from 3Q to 4Q. Does that impact your capitated revenue in 3Q?

And what gives you the confidence that the overall 2026 guidance is even higher than you previously guided before?

It does impact 3Q revenue, specifically for the capitated segment. But as we reaffirm today, we still expect approximately $150 million of capitated revenue this year.

Our Specialty Pharmacy segment this year continues to surpass our own expectations. That was the significance behind the raise there on revenue, but we're still confident in the pipeline and the launches that we've called out.

Yuan, it's Dan. The only other things I would add to that are that the exclusivity obtained this quarter in California was not part of the initial forecast nor was the 2 contracts, Oregon and Nevada.

So there have been, in addition to that statewide contract pushing by couple of months, having some unforecast wins as well on the capitation side.

Got it. Maybe my last question, if we take a step back for your covered Medi-Cal lives in California in 2027, how do you expect the number to change considering the work requirement and then the new added 230,000 covered lives?

Yes. So I'd say, broadly speaking, our total capitated Medi-Cal lives go up.

We don't have a precise full year 2027 number on that, but certainly, the exclusivity that we have gained this quarter from an existing partner, which is heavily Medi-Cal-based is going to cause that rise as well as some additional pipeline opportunities on Medi-Cal. As far as the macro-related shifts in Medi-Cal membership next year, which that will be offset, I would expect it to be fairly small, but we don't have clear guidance on that yet.

First off, I apologize if this was already addressed. But on the Specialty Pharmacy business, it looks like gross margin ticked up pretty healthily here from Q1 to Q2.

Is this kind of a new normal? Is there -- what drove that?

And is this sustainable?

Ben, it's certainly being helped by some specific initiatives within our drug procurement department. And so the nature of those types of initiatives are temporary.

We are certainly outpacing the market right now, and it's fantastic for the business. I would expect that over the coming quarters, it comes down slightly, but still certainly in the high teens.

And we're constantly looking for new opportunities to expand margin and to generate opportunities like we've seen in the second quarter.

Okay. Got it.

And then on the 130,000 lives shifting by a couple of months, why did that slip? Any more color that you can provide there?

Yes. It was just frankly related to delays in processes related at sort of the payer level with getting that set up.

So nothing related at all to the contract itself or confidence in the contract, just a process-related issue.

Makes sense. And then lastly for me is now that you're providing the MLR, any chance of getting visits [indiscernible]?

Of getting what then?

Visits, total visits.

Total visits. It's certainly something we can discuss.

Thanks so much for the thoughtful questions. Again, we're very pleased with the results this past quarter and look forward to providing more updates to the company in the future.

Thank you so much.